Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 7/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317332 | 1.00 | PDPK1 (0.54) | PDPK1AURKBROCK1AURKAPIK3CG | |
| SCHEMBL1317327 | 1.00 | PDPK1 (0.54) | PDPK1AURKBROCK1AURKAPIK3CG | |
| SCHEMBL1319135 | 0.99 | PDPK1 (0.53) | PDPK1AURKBROCK1AURKAPIK3CG | |
| SCHEMBL1319134 | 0.99 | PDPK1 (0.53) | PDPK1AURKBROCK1AURKAPIK3CG | |
| SCHEMBL1319137 | 0.99 | PDPK1 (0.53) | PDPK1AURKBROCK1AURKAPIK3CG | |
| SCHEMBL1318575 | 0.91 | PDPK1 (0.65) | PDPK1AURKBROCK1AURKAPIK3CG | |
| SCHEMBL12122771 | 0.88 | PDPK1 (0.60) | PDPK1AURKBROCK1AURKAPIK3CG | |
| SCHEMBL1317603 | 0.86 | PDPK1 (0.41) | PDPK1AURKBROCK1AURKAPIK3CG | |
| SCHEMBL1317605 | 0.86 | PDPK1 (0.41) | PDPK1AURKBROCK1AURKAPIK3CG | |
| SCHEMBL1317604 | 0.86 | PDPK1 (0.41) | PDPK1AURKBROCK1AURKAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | PDPK1 12/4885AURKB 262/4885ROCK1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.